Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(11); doi: 10.25236/AJMHS.2023.041110.

Research Status and Progress of Cerebral Glioblastoma


Zhang Peiyun1, Liu Lei1, Li Xinping1, Yu Hubin1, Zhang Yami2

Corresponding Author:
Zhang Yami

1Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China

2Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China


Glioblastoma is the primary malignant tumor with the highest incidence of central nervous system in adults. Due to its high heterogeneity, strong invasiveness, blood-brain barrier and other characteristics, the therapeutic effect is not ideal, which seriously threatens the life health and safety of patients. In recent years, with the deepening of the research on the basic and clinical characteristics of glioma, the research of glioblastoma has been further developed. This article reviews the epidemiology, pathogenesis, clinical features, histopathological changes, imaging features and treatment methods of glioma in order to provide reference for the treatment of glioma.


Glioblastoma; Research status; Research progress

Cite This Paper

Zhang Peiyun, Liu Lei, Li Xinping, Yu Hubin, Zhang Yami. Research Status and Progress of Cerebral Glioblastoma. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 11: 68-74. https://doi.org/10.25236/AJMHS.2023.041110.


[1] Jia Guoping, Li Xin, Song Yuqian, et al. Glypican-1 expression in gliomas and its relationship with clinicopathological features and prognosis [J]. China Journal of Modern Medicine, 2020, 30(14):19-23.

[2] Ostrom Quinn T, Price Mackenzie, Neff Corey, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019 [J]. Neuro-oncology, 2022, 24(5): vv1-v95.

[3] Bao Yifeng, Yang Minfeng, Jin Chunjing, et al. Preoperative hematologic inflammatory markers as prognostic factors in patients with glioma [J]. World Neurosurgery, 2018, 119:e710-e716.

[4] Batash Ron, Asna Noam, Schaffer Pamela, et al. Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review [J]. Current medicinal chemistry, 2017, 24(27):3002-3009.

[5] Stupp R, Tonn J-C, Brada M, et al. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Annals of oncology: official journal of the European Society for Medical Oncology, 2010, 215(5): v190-193.

[6] National Health Commission Medical Administration Bureau, Chinese Anti-Cancer Association Brain glioma Professional Committee, Chinese Medical Doctor Association Brain glioma Professional Committee. Glioma Diagnosis and Treatment Guidelines (2022 edition) [J]. Chinese Journal of Neurosurgery, 2022, 38(8):757-777.

[7] Sarah Lapointe, Arie Perry, Nicholas A Butowski, et al. Primary brain tumours in adults [J]. The Lancet, 2018, 392(10145):432-446. 

[8] Wesseling P, Capper D. WHO 2016 Classification of gliomas [J]. Neuropathology and applied neurobiology, 2018, 44(2):139-150. 

[9] Chen Si, Lu Bin, Bi Kun, Yin Wenwei. Glycyrrhizic acid inhibits the growth of glioma cells by activating TRPV4-induced mitophagy [J]. Journal of Modern Oncology, 2023, 31(15):2776-2781. 

[10] Chen Ran, Gao Xiang, Zhang Shucai, Ma Li. Current status and progress of medical treatment of high-grade glioma [J]. Journal of Shandong First Medical University & Shandong Academy of Medical Sciences, 2023, 44(6):444-451. 

[11] Louis David N, Perry Arie, Reifenberger Guido, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary [J]. Acta neuropathologica, 2016, 131(6):803-820.  

[12] Supriya Mallick, Rony Benson, Abdul Hakim, et al. Management of glioblastoma after recurrence: A changing paradigm [J]. Journal of the Egyptian National Cancer Institute, 2016, 28(4):199-210. 

[13] Silvia Matteoni, Claudia Abbruzzese, Veronica Villani, et al. The influence of patient sex on clinical approaches to malignant glioma [J]. Cancer Letters, 2020, 468:41-47.  

[14] Jeong Woojin, Lee Duck-Yeon, Park Sunjoo, et al. ERp16, an endoplasmic reticulum-resident thiol-disulfide oxidoreductase: biochemical properties and role in apoptosis induced by endoplasmic reticulum stress [J]. The Journal of biological chemistry, 2008, 283(37): 25557-25566. 

[15] Zhang Luyao, Yuan Hongping, Wang Xiaoxuan, et al. Silencing TXNDC12 by shRNA inhibits the proliferation and migration of glioma cells [J]. Chinese Journal of Clinical and Experimental Pathology, 2023, 39(5): 519-524. 

[16] Liu Zhan, Wei Qiming, Li Ying. Molecular mechanism of lncRNA DNAJC3-AS1/miR-3619-5p axis influencing migration,invasion and epithelial-mesenchymal transition of glioma cells [J]. Chinese Journal of Immunology, 2022, 38(21):2611-2616. 

[17] Yao Jingjing, Meng Yiting, Li Li, Yin Hongfang. The pathogenesis of diffuse midline glioma induced by histone H3K27M [J]. Chinese Journal of Clinical and Experimental Pathology, 2022, 38(2):200-203. 

[18] Ghavami Saeid, Rashedi Iran, Dattilo Brian M, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway [J]. Journal of leukocyte biology, 2008, 83(6):1484-1492.

[19] Palumbo Roberta, Galvez Beatriz G, Pusterla Tobias, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation [J]. The Journal of Experimental Medicine, 2007, 204(11): i24-i24.

[20] Liang Huasheng, Zhong Yuhua, Zhou Shaobi, et al. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo [J]. Cancer Letters, 2011, 313(1):91-98. 

[21] China Anti-Cancer Association Committee of Glioma, Jiang Tao, Zhang Wei, Wang Zheng. China Anti-Cancer Association guidelines for integrative diagnosis and treatment of glioma (abridged version) [J]. Chinese Journal of Clinical Oncology, 2022, 49(16): 811-818. 

[22] Hu Huimin, Mu Quanhua, Bao Zhaoshi, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor [J]. Cell, 2018, 175(6):1665-1678. 

[23] Reiss Samantha N, Yerram Prakirthi, Modelevsky Lisa, et al. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas [J]. Journal for immunotherapy of cancer, 2017, 5(1):99. 

[24] Ma Qingyou, Geng Qilong, Wang Fafen. Application Value of Magnetic Resonance Imaging in Differential Diagnosis of Glioma [J]. Chinese Community Doctors, 2022, 38(16):96-98.

[25] Jiang Tao. Advances in the treatment of brain glioma [M]. Beijing: People's Medical Publishing House, 2011:12. 

[26] Mao Ying, Zhou Liangfu. Chinese Guidelines for the Diagnosis and Treatment of Central Nervous System Glioma (2015) [J]. National Medical Journal of China, 2016, 96(7): 481-481.

[27] Chen Ricky, Ravindra Vijay M, Cohen Adam L, et al. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas [J]. Neurosurgical focus, 2015, 38(3):E2. 

[28] O. van Tellingen, B. Yetkin-Arik, M.C. de Gooijer, et al. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment [J]. Drug Resistance Updates, 2015, 19:1-12. 

[29] Hadjipanayis Costas G, Widhalm Georg, Stummer Walter, et al. What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas? [J]. Neurosurgery, 2015, 77(5):663-673. 

[30] Feng Baofeng. The treatment of brain glioma with Chinese Traditional medicine [J]. Chinese Medicine Modern Distance Education of China, 2011, 9(5):170-171. 

[31] Hu Ting, Zhong Xueyun. Roles of microRNAs in glioma [J]. Chinese Journal of Pathophysiology, 2011, 27(7):1431-1437+1444.

[32] Liu Huating, Yang Tianming. Treatment Strategy for Glioma [J]. Progress in Modern Biomedicine, 2011, 11(5):958-960.

[33] Zhang Chengxiang, Zhao Weiyu, Liu Lei, et al. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment [J]. Oncotarget, 2015, 6(32):32681-32700. 

[34] Capdevila Laia, Cros Sara, Ramirez Jose-Luis, et al. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation [J]. Journal of neuro-oncology, 2014, 117(1):77-84. 

[35] Fei Fan, He Yongsheng. Molecular targeted therapy and optimal treatment for gliomas [J]. Practical Journal of Clinical Medicine, 2011, 8(2):199-201.

[36] Cheng Lidong, Liu Jingdian, Shu Kai. Current status and progress of molecular research and targeted therapy for glioma [J]. Journal of Clinical Surgery, 2022, 30(10):998-1000.

[37] Zhang Qian, Cao Bei. Recent advance in immunotherapy for glioblastoma multiforme [J]. Chinese Journal of Neuromedicine, 2016, 15(8):856-859.

[38] Tivnan Amanda, Heilinger Tatjana, Lavelle Ed C, et al. Advances in immunotherapy for the treatment of glioblastoma [J]. Journal of neuro-oncology, 2017, 131(1):1-9. 

[39] Li Lin, Liu Chao, Shao Jiang, et al. Research progress of tumor treating fields in the treatment of glioma [J]. The Journal of Practical Medicine, 2022, 38(22):2763-2767.

[40] Ghiaseddin Ashley P, Shin David, Melnick Kaitlyn, et al. Tumor Treating Fields in the Management of Patients with Malignant Gliomas [J]. Current treatment options in oncology, 2020, 21(9):76. 

[41] Regev Ohad, Merkin Vladimir, Blumenthal Deborah T, et al. Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis [J]. Neuro-Oncology Practice, 2021, 8(4):426-440. 

[42] Jin Lei, Guo Shenquan, Zhang Xin, et al. Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis [J]. Neurosurgical review, 2020, 44(4):1-13. 

[43] Guberina N, Pöttgen C, Kebir S, et al. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial [J]. Radiation oncology (London, England), 2020, 15(1):83. 

[44] Gil Miguel J, de Las Peñas Ramón, Reynés Gaspar, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO) [J]. Anti-cancer drugs, 2012, 23(6):659-665.